Drug Lobby Touts Pfizer’s Kickback Challenge At High Court

By Jeff Overley (November 14, 2022, 11:26 PM EST) — The pharmaceutical industry’s largest lobbying group Monday threw its weight behind Pfizer’s attack on federal health-fraud enforcers, warning the U.S. Supreme Court that capacious views of a key kickback law have “far-reaching implications” for prosecutorial powers and whistleblower-led litigation….

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

• Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
• Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
• Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

No Byline Policy

Editorial Guidelines

Corrections Policy

Source